Related Experiment Videos
Serum adenosine deaminase activity in brain tumours
Acta Neurochirurgica
|January 1, 1993
Summary
Serum adenosine deaminase (ADA) levels were similar in brain tumor patients and healthy individuals. This suggests cell-mediated immunity may not significantly impact intracranial tumors.
Area of Science:
- Neuroscience
- Immunology
- Oncology
Background:
- Adenosine deaminase (ADA) is an enzyme crucial for purine metabolism and lymphocyte maturation.
- Elevated ADA levels are observed in various neoplastic conditions, indicating potential immune system involvement.
Purpose of the Study:
- To investigate serum adenosine deaminase (ADA) activity in patients with intracranial tumors.
- To determine the role of cell-mediated immunity in the pathogenesis of brain tumors.
Main Methods:
- Serum samples were collected from 86 patients diagnosed with intracranial tumors.
- Serum ADA activity was measured and compared to that of 40 healthy control volunteers.
Main Results:
- No significant difference was found in serum ADA activity between patients with intracranial tumors and healthy controls.
- Observed ADA concentrations in biological fluids and tumor tissues in other cancers did not correlate with brain tumor findings.
Conclusions:
- Serum ADA levels do not appear to be a reliable biomarker for intracranial tumors.
- Cell-mediated immunity likely plays a limited role in the development or progression of brain tumors.